CRISPR and Cancer

Caribou Biosciences expands its clinical programme for CB-010 with FDA nod to initiate clinical trial in lupus, Verve Therapeutics pauses ongoing...

Researchers in Germany report that CRISPR-Cas9-mediated knockout of the tyrosine kinase MerTK reduces cancer cell proliferation and migration in vitro...

In this update, we highlight recent news on Poseida Therapeutics' fully allogeneic CAR-T candidate for multiple myeloma (P-BCMA-ALLO1), Intellia's and...

AvenCell Therapeutics recently announced that the first patient has been dosed in a Phase 1A study with its lead product candidate AVC-201. This novel...

For the inaugural episode of CMN Live on 26th January 2024, we spoke with Eric Kmiec, Ph.D. about the successes of therapeutic gene editing to date,...

As 2023 draws to a close, we look back on some of the major clinical highlights from the year gone by.

Caribou Biosciences gets closer to Phase 3 with its gene-edited cell therapy candidate for large B-cell lymphoma, and Editas Medicine reports positive...

In this article, we look at recent clinical updates from the gene-editing field. These updates include clinical data from Vor Bio's ongoing Phase 1/2a...